Business Wire

W Green Pay (WGP) - The Global Solution to Greenhouse Gas (GHG) Reduction

Share

W-Foundation (www.gcrfund.org/en/), the philanthropic foundation behind HOOXI campaign, Global Nature Conservation Campaign, introduces W Green Pay (WGP), the ERC20-compliant blockchain, to reward HOOXI app users for their Greenhouse Gas (GHG) reduction efforts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180530005620/en/

(Graphic: W-Foundation)

(Graphic: W-Foundation)

Korean government officials attended and shared congratulatory messages at the “Nation-wide Public Movement to Reduce GHG Emission (HOOXI Campaign)” Declaration and Committee Inauguration Ceremony held at National Assembly in December 2017 and April 2018: Kim, Eunkyung (Minister, Ministry of Environment), Kim, Hyunmee (Minister, Ministry of Land, Infrastructure, and Transport), Jeong, Segyun (Chairman, National Assembly), Choo, Miae (Representative Member, Democratic Party – the ruling party), Im, Jongseong (Member, National Assembly), and many more.

Sustainable business model: Globally first to reward individuals in carbon market

HOOXI app will aggregate the GHG reduction data of individuals, for which Korean government will allocate NEPs (National Emission Permit: trades at approximately US$20 for 1 ton). With revenue from the allocated NEPs traded at the market, HOOXI app will fund its operations and the ongoing market purchase of WGP to reward users.

HOOXI app: Gamification features with instantaneous rewards (WGP)

HOOXI app offers a variety of functional advantages.

First, HOOXI app is a ground-breaking platform digitizing public participation and rewards for GHG reduction efforts.

Second, HOOXI app is a mobile app-based environmental encyclopedia. HOOXI app provides easily executable ways to reduce GHG in everyday life, and information on environmental impacts driven by user participation.

Third, HOOXI app uses artificial intelligence (AI) to analyze the profile of each user and customize missions for their lifestyle, age, gender, occupation. Based on these analyzed information, tailored daily, weekly and monthly GHG reduction missions will be sent to users.

Fourth, HOOXI app incentivizes users through its gamification features. HOOXI app can track users’ daily exercise stats as Fitbit does and suggest location-based missions as Pokémon Go’s does. Based on their completed mission points, users can track their ranks and compete within and between their groups, i.e. friends, companies, and the entire country.

Fifth, think of the likes on your Instagram posts — we are constantly endeavoring to achieve and be rewarded instantaneously. With its social networking service features, HOOXI app encourages users to get on the app daily to earn rewards.

Using WGP: Shopping, cashback and more

Users can use WGP tokens in different channels. W-Foundation’s HOOXI mall and partnered-online and offline retail stores will accept WGP for payment. WGP-affiliated credit card with Korean commercial banks will also be launched, with WGP as a payback system for credit card users.

W-Foundation continues to work on HOOXI app’s development as well as WGP’s utility. “As more users join, HOOXI app will extract a greater value from the carbon market and enhance WGP’s value and liquidity to its holders,” said Youree Lee, CEO of W-Foundation.

Subscribe on W Green Pay (WGP) website ( www.wpay.sg ), for promotions and exclusive updates.

Contact information

Media Enquiries
W-Foundation
Michael Lee
michael@wfoundation.kr

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing